证券代码：688217 证券简称：睿昂基因 公告编号：2025-020 上海睿昂基因科技股份有限公司 关于 2024 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海睿昂基因科技股份有限公司（以下简称"公司"）2024 年度拟不进行 利润分配，不派发现金红利，不送红股，不以资本公积转增股本，剩余未分配利 润 13,826.49 万元滚存至下一年度。 公司 2024 年度拟不进行利润分配，已充分考虑到行业发展情况、公司发 展阶段、研发项目及经营规模扩大，资金需求较大等各方面因素。 公司 2024 年度利润分配预案已经公司第三届董事会第二次会议和第三 届监事会第二次会议审议通过，尚需提交公司 2024 年年度股东大会审议。 本次利润分配预案的实施不会触及《上海证券交易所科创板股票上市规 则（2024 年 4 月修订）》第 12.9.1 条第一款第（八）项规定的可能被实施其他 风险警示的情形。 一、利润分配预案内容 经中汇会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 ...

Financial Performance - The company reported a net profit attributable to shareholders of -15.76 million yuan for 2024, leading to a decision not to distribute cash dividends or increase capital reserves [8]. - The company's operating revenue for 2024 was CNY 242.31 million, a decrease of 6.16% compared to CNY 258.21 million in 2023 [24]. - The net profit attributable to shareholders for 2024 was a loss of CNY 15.76 million, a decline of 298.78% from a profit of CNY 7.93 million in 2023 [24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of CNY 19.25 million in 2024, compared to a profit of CNY 3.70 million in 2023, marking a decline of 620.88% [24]. - The company reported a decrease of 4.51% in revenue after excluding non-core business income, totaling CNY 234.95 million in 2024 [24]. - The company experienced increased costs due to credit impairment losses and legal consultation fees related to executive events [4]. - The company faced a decline in revenue and profit due to industry demand fluctuations and increased competition, resulting in a decrease in product prices [4]. - The company reported a significant increase in asset impairment losses, which rose by 100.06% year-on-year [152]. - The company experienced a 39.62% decline in investment income, totaling CNY 1.62 million [149]. - The company reported a 90.52% decrease in non-operating expenses, amounting to CNY 294,250.75 [149]. Research and Development - The company plans to continue focusing on its core business and enhance its competitive edge by increasing R&D investment [4]. - R&D investment for 2024 was 62.47 million RMB, accounting for 25.78% of the current operating revenue [35]. - Total R&D investment for the year was CNY 62.47 million, a decrease of 10.50% compared to the previous year, with R&D expenses accounting for 25.78% of operating revenue [113]. - The number of R&D personnel decreased from 99 to 76, with R&D personnel now representing 18.95% of the total workforce [121]. - The average salary of R&D personnel increased to 25.38 thousand RMB, compared to 20.09 thousand RMB in the previous period [121]. - The company has established a strong core R&D team, with key personnel having extensive experience and educational backgrounds from prestigious institutions [123]. - The company has developed an AI-based multi-omics analysis platform utilizing a database of over 10,000 patients, enhancing its data-driven decision-making capabilities [124]. - The company is focusing on blood cancer precision diagnostics and related minimal residual disease detection, pausing some projects in solid tumors and pathogen microbiology [120]. Product Development and Market Position - The company is committed to the national strategy of "precision medicine" by providing self-branded molecular diagnostic reagents and services [4]. - The company has developed 107 in vitro diagnostic reagent kits, with 31 classified as Class III medical devices, covering blood diseases, solid tumors, and infectious diseases [64]. - The company has launched several unique diagnostic products, including the first approved molecular diagnostic kits for leukemia and solid tumors in China, significantly enhancing its market position [64][65]. - The company has established partnerships with multiple hospitals for various research projects, including the molecular typing of AML and B-ALL, enhancing its research capabilities [50]. - The company achieved a daily testing capacity of 20,000 samples in its upgraded intelligent laboratory, significantly improving testing efficiency [55]. - The company has received approval for multiple gene mutation detection kits, including a kit for acute myeloid leukemia (AML) with a market size of 3,000 million RMB, and a kit for diffuse large B-cell lymphoma with a market size of 5,000 million RMB [117]. - The company is actively pursuing academic collaborations, with multiple research papers published in reputable journals, enhancing its market presence and credibility [38][39][40]. Market Challenges and Risks - The company faces risks of declining revenue and profit due to industry demand fluctuations and increased competition, with potential short-term performance pressure [131]. - The company is at risk of new product development failures due to high costs and long development cycles, which could impact its competitive edge [133]. - The company must maintain quality control across its expanding operations to avoid product quality risks that could harm its reputation [139]. - The company has 12 third-class medical device products pending registration, with potential delays due to regulatory changes posing a risk to timely market entry [134]. Operational Efficiency - The net cash flow from operating activities increased by 33.00% to CNY 59.98 million in 2024, compared to CNY 45.10 million in 2023 [24]. - The company’s financial statements received an unqualified audit opinion with emphasis on certain matters [6]. - The company has continuously updated its internal control systems to enhance governance and risk management practices [56]. - The company is continuing to utilize its raised funds under the supervision of Guotai Junan Securities Co., Ltd. for ongoing projects [23]. Sales and Revenue Breakdown - Revenue from leukemia molecular detection kits was 137.78 million RMB, a year-on-year decrease of 3.49% [34]. - Revenue from lymphoma rearrangement detection kits increased by 12.55% to 36.66 million RMB [34]. - The company’s testing services revenue was 20.65 million RMB, down 12.08% year-on-year, while research services revenue fell by 24.97% to 4.61 million RMB [153]. - The gross margin for in vitro diagnostic products was 75.90%, an increase of 1.04 percentage points compared to the previous year [154]. - The company reported a significant increase in accounts receivable by 1,355.50% to 46.86 million RMB compared to the previous year [176]. Strategic Partnerships and Collaborations - The company collaborates with top hospitals and universities, enhancing its brand influence and recognition in the molecular diagnostics field [130]. - The company has established stable partnerships with over 70 hospitals for its early-stage molecular diagnostic products for solid tumors [81]. - The company is focusing on strategic partnerships with leading reagent companies to leverage advanced technology platforms for market entry [102].

地址：上海市浦东新区银城中路 501 号上海中心大厦 11、12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海睿昂基因科技股份有限公司 2022 年限制性股票激励计划作废部分已授予 尚未归属的限制性股票的 法律意见书 上海市锦天城律师事务所 关于上海睿昂基因科技股份有限公司 2022 年限制性股票激励计划作废部分已授予 尚未归属的限制性股票的 法律意见书 案号：01F20221079 致：上海睿昂基因科技股份有限公司 上海市锦天城律师事务所（以下简称"锦天城"或"本所"）接受上海睿昂 基因科技股份有限公司（以下简称"公司"或"睿昂基因"）的委托，担任公司 "2022 年限制性股票股权激励计划"（以下简称"本激励计划"或"本次激励 计划"）的法律顾问，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、中国证券监督管理委 员会（以下简称"中国证监会"）、《上市公司股权激励管理办法》（以下简称 "《管理办法》"）、《上海证券交易所科创板股票上市规 ...

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海睿昂基因科技股份有限公司（以下简称"公司"）于 2025 年 4 月 16 日 召开第三届董事会第二次会议和第三届监事会第二次会议，审议通过了《关于作 废 2022 年限制性股票激励计划部分已授予尚未归属的限制性股票的议案》，现将 有关事项说明如下： 一、公司 2022 年限制性股票激励计划已履行的决策程序和信息披露情况 1、2022 年 3 月 10 日，公司召开第二届董事会第二次会议，审议通过了《关 于公司<2022 年限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2022 年限制性股票激励计划实施考核管理办法>的议案》《关于提请公司股东大会授权 董事会办理股权激励相关事宜的议案》等相关议案。公司独立董事就激励计划相 关议案发表了独立意见。 同日，公司召开第二届监事会第二次会议，审议通过了《关于公司<2022 年 限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2022 年限制性股票 激励计划实施考核管理办法>的议案》《关于核实公司<2022 年限制性股票 ...

| 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.2800 | 0.1400 | -300 | 0.7300 | | 每股净资产（元） | 16.28 | 16.93 | -3.84 | 16.86 | | 每股公积金(元) | 13.11 | 13.17 | -0.46 | 13.05 | | 每股未分配利润(元) | 2.48 | 2.76 | -10.14 | 2.81 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 2.42 | 2.58 | -6.2 | 4.24 | | 净利润(亿元) | -0.16 | 0.08 | -300 | 0.4 | | 净资产收益率(%) | -1.71 | 0.84 | -303.57 | 4.43 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 2738.78万股，累计占流通股比： 49.04%，较上期变化： -21 ...

睿昂基因公告，2024年营业收入为2.42亿元，同比下降6.16%；归属于上市公司股东的净亏损1576.45万 元，去年同期净利润793.07万元；基本每股收益-0.28元／股。2024年度拟不派发现金红利，不送红股， 不以资本公积转增股本，剩余未分配利润1.38亿元滚存至下一年度。 ...

股东方面，截至2024年9月30日，睿昂基因股东户数4658户，较上次增加641户，户均持股市值35.28万 元，户均持股数量2.76万股。 4月16日，睿昂基因今日收盘20.61元，下跌2.14%，最新市净率1.24，总市值11.51亿元。 最新一期业绩显示，2024年三季报，公司实现营业收入1.90亿元，同比-4.62%；净利润572.73万元，同 比-69.58%，销售毛利率76.08%。 来源：金融界 上海睿昂基因科技股份有限公司的主营业务是体外诊断产品的研发、生产、销售及科研服务；公司的主 要产品是分子诊断试剂。佰睿达是国内获批上市的白血病检测试剂盒中覆盖融合基因种类最多产品。公 司也凭借该产品继续强势领跑国内白血病分子诊断行业。公司先后获得了"上海市专精特新企业"、"奉 贤区科技小巨人企业"等荣誉称号，并多次承担由国家科技部、上海市科学技术委员会、上海张江高新 技术产业开发区管理委员会等部门主导的多个重大科研项目。 序号股票简称PE(TTM)PE(静)市净率总市值(元)8睿昂基因-79.59-79.591.2411.51亿行业平均 45.9448.384.71101.41亿行业中值29.6428. ...

睿昂基因688217 时间: 2025年4月1日星期二 42.73分综合得分 偏弱 趋势方向 主力成本分析 21.70 元 当日主力成本 21.42 元 5日主力成本 22.40 元 20日主力成本 21.14 元 60日主力成本 周期内涨跌停 过去一年内该股 涨停 0次 跌停 1 次 技术面分析 21.52 短期压力位 21.01 短期支撑位 23.38 中期压力位 21.01 中期支撑位 股价突破短期压力位，短线有望走强； 目前中期趋势不慎明朗，静待主力资金选择方向 K线形态 ★多方炮★ 在底部出现有上涨可能，在中间出现有可能是上涨中继，顶部出现是复合见顶信号 资金流数据 2025年04月01日的资金流向数据方面 | 主力资金净流入343.33万元 | | --- | | 占总成交额13% | | 超大单净流入31.74万元 | | 大单净流入311.58万元 | | 散户资金净流出88.79万 | 关联行业/概念板块 医疗器械 3.23%、体外诊断 3.16%、医疗器械概念 2.35%、基因测序 2.46%等 （以上内容为自选股写手差分机完成，仅作为用户看盘参考，不能作为操作依据。） 风险提示：以上内容 ...

Financial Performance - Total revenue for 2024 was RMB 241.87 million, a decrease of 6.33% compared to the previous year[2] - Net profit attributable to the parent company was -RMB 14.46 million, a decline of 282.38% year-on-year[2] - Basic earnings per share were -RMB 0.26, down 285.71% from the previous year[2] - The company's equity attributable to shareholders decreased by 3.72% to RMB 910.56 million[3] Assets and Impairments - Total assets at the end of the reporting period were RMB 997.11 million, a decrease of 4.51% from the beginning of the period[2] - The company recognized goodwill impairment of RMB 14.30 million, an increase of RMB 6.81 million compared to the previous year[6] - Credit impairment losses on accounts receivable increased by RMB 3.80 million due to slower customer payments[6] Challenges and Costs - The company faced challenges due to the downturn in the medical industry and executive events, impacting revenue expectations[5] - Legal consulting fees related to executive events amounted to RMB 4.51 million, which was not present in the previous year[6] Data Disclaimer - The company emphasizes the preliminary nature of the financial data, which is subject to audit and final confirmation in the annual report[7]